Anavex Life Sciences Announces Issuance of New U.S. Patent ANAVEX®2-73 (blarcamesine)

Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD

Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as VP Head of Biostatistics

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

Anavex Life Sciences Announces Exceeding of Enrollment Target for ANAVEX®2-73 (blarcamesine)

Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on February 7, 2023

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022